<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02996448</url>
  </required_header>
  <id_info>
    <org_study_id>170017</org_study_id>
    <secondary_id>17-I-0017</secondary_id>
    <nct_id>NCT02996448</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome</brief_title>
  <official_title>A Phase 2a Study to Evaluate the Safety, Tolerability, and Immunogenicity of One Dose of NDV-3A Vaccine in Patients With STAT3-Mutated Hyper-IgE Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      AD-HIES is a disease that weakens the immune system. It puts people at risk for infections,&#xD;
      particularly Staph and Candida infections. Researchers want to test a vaccine that may help&#xD;
      keep people from getting these infections, which would help people with AD-HIES.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To test the new vaccine NDV-3A for protection against infection from the yeast Candida and&#xD;
      the bacterium Staphylococcus aureus (Staph).&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Adults ages 18-55 who have AD-HIES&#xD;
&#xD;
      Healthy volunteers ages 18-55&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will have 6-7 study visits over 6-7 months. They will also be contacted by phone&#xD;
      in between some visits.&#xD;
&#xD;
      Participants will be screened with a medical history, physical exam, and blood and urine&#xD;
      tests.&#xD;
&#xD;
      Participants will have 2 baseline visits. They will have repeat the screening tests. They&#xD;
      will have samples of saliva, stool, skin, mucus (oral, nasal, and/or vaginal) collected.&#xD;
      Vaginal and stool samples are optional. Any eczema on their skin will be looked at.&#xD;
&#xD;
      Participants will fill out symptom diary cards to record how they feel.&#xD;
&#xD;
      Participants will have the NDV-3A vaccine injected into a muscle in the arm.&#xD;
&#xD;
      Participants will return the next 2 days. They will have a physical exam. Blood will be&#xD;
      collected.&#xD;
&#xD;
      Participants will have 2 more follow-up visits at the NIH. They will have a physical exam.&#xD;
      They will have blood, saliva, stool, skin, vaginal fluid, and/or mucus samples collected.&#xD;
      Vaginal and stool samples are optional.&#xD;
&#xD;
      Participants will be called once a month for 5 months after the vaccination. There is an&#xD;
      optional visit about 6 weeks after the vaccination. Participants will provide a blood sample&#xD;
      at this visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autosomal-dominant hyper-IgE syndrome (AD-HIES) is characterized by recurrent Staphylococcus&#xD;
      aureus and Candida epithelial infections, which is thought to be due, in part, to a lack of&#xD;
      Th17 cell differentiation, thus impairing epithelial immunity. Treatment of AD-HIES is&#xD;
      primarily supportive with prophylactic antibiotics; however, this is limited by microbial&#xD;
      resistance and intolerance of medications, and infections do still occur. Immunological&#xD;
      intervention with a vaccine could improve quality of life by preventing these infections&#xD;
      altogether.&#xD;
&#xD;
      The NDV-3A vaccine consists of a recombinant protein derived from the Candida Als3 adhesion&#xD;
      protein. This protein is homologous to surface proteins on S aureus and has been shown in&#xD;
      preclinical studies to protect against both intravascular and subcutaneous challenge with S&#xD;
      aureus. Therefore, NDV-3A represents not only the first antifungal vaccine, but also the&#xD;
      first vaccine to provide cross-kingdom protection. In Phase 1 and Phase 2 studies in healthy&#xD;
      volunteers (150 receiving vaccine), the safety profile of this vaccine is very reassuring as&#xD;
      the vaccine elicits a strong antibody response after a single dose in all vaccinees as well&#xD;
      as a Th1 and/or Th17 response in the majority of vaccinees. We will enroll 20 healthy adult&#xD;
      volunteers and 20 adults with AD-HIES in an open-label, single-dose study to assess the&#xD;
      immunological response to and the safety/tolerability of the NDV-3A vaccine. We anticipate an&#xD;
      increase in baseline anti-Als3 IgG within 2 weeks post-vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Safety concerns led to early termination.&#xD;
  </why_stopped>
  <start_date>November 17, 2016</start_date>
  <completion_date type="Actual">October 9, 2018</completion_date>
  <primary_completion_date type="Actual">July 22, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Each Group With at Least a Four-fold Increase in Anti rAls3 Antibody Titer.</measure>
    <time_frame>2 weeks after vaccination</time_frame>
    <description>Antibody titer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events That Led to Study Termination.</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Als3 Antibody Titers at 6 Months After Vaccination in Patients With AD HIES and Healthy Volunteers.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Autosomal-dominant Hyper-IgE Syndrome</condition>
  <arm_group>
    <arm_group_label>NDV 3A vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NDV-3A</intervention_name>
    <description>A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.</description>
    <arm_group_label>NDV 3A vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Age 18-55 years.&#xD;
&#xD;
               2. For healthy volunteers: in general good health, without significant medical&#xD;
                  illness, physical exam findings, or significant laboratory abnormalities as&#xD;
                  determined by the investigator.&#xD;
&#xD;
               3. For participants with AD-HIES: confirmation of diagnosis with a STAT3 mutation.&#xD;
&#xD;
               4. Participants who can get pregnant must be willing to use an acceptable form of&#xD;
                  contraception for the duration of participation and have a negative pregnancy&#xD;
                  test at screening.&#xD;
&#xD;
               5. Agree to allow storage of biological samples for future research.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Has a history of allergic response or other serious reaction to aluminum and/or yeast&#xD;
             products.&#xD;
&#xD;
          2. Has a history of clinically significant allergy including anaphylaxis or other serious&#xD;
             reaction to food, vaccines, or other drugs, that in the opinion of the investigator,&#xD;
             might put the participant at undue risk.&#xD;
&#xD;
          3. Has an active infection (such as S aureus abscess, pneumonia, acute Candida&#xD;
             mucocutaneous infection). Baseline state of chronic infections will be considered by&#xD;
             the PI (eg, chronic Pseudomonas infection in lung).&#xD;
&#xD;
          4. Has an active infection with hepatitis B, hepatitis C, or HIV.&#xD;
&#xD;
          5. Has received or is planning to receive any investigational drug, investigational&#xD;
             vaccine, or investigational device within four weeks prior to vaccination, or at any&#xD;
             other time during their participation in the study.&#xD;
&#xD;
          6. Has received or is planning to receive any other live vaccine within three weeks&#xD;
             before vaccination or for three weeks after vaccination.&#xD;
&#xD;
          7. Self-reported current alcohol abuse or addiction.&#xD;
&#xD;
          8. Self-reported current illicit drug abuse or addiction, or drug screen positive for&#xD;
             illicit drugs.&#xD;
&#xD;
          9. Current or planned use, within 3 weeks before vaccination, of any medications or&#xD;
             treatments that may alter immune responses to the study vaccine (eg, immunosuppressive&#xD;
             medications including systemic corticosteroids, cyclosporine, tacrolimus, cytotoxic&#xD;
             drugs, Bacillus Calmette-Guerin, monoclonal antibodies, or radiation therapy).&#xD;
             Topical, intranasal, or inhaled immunosuppressants such as corticosteroids will be&#xD;
             allowed.&#xD;
&#xD;
         10. Current or planned use within 2 weeks before vaccination of immune globulin&#xD;
             replacement.&#xD;
&#xD;
         11. Has any of the following laboratory abnormalities at the screening visit:&#xD;
&#xD;
               1. Alanine transaminase (ALT), aspartate transaminase (AST), and/or alkaline&#xD;
&#xD;
                  phosphatase (ALP) &gt; 1.5 times the upper limit of normal (ULN).&#xD;
&#xD;
               2. Total bilirubin level &gt; 1.5 times the ULN&#xD;
&#xD;
               3. Serum creatinine level &gt; 1.5 times the ULN&#xD;
&#xD;
               4. Absolute neutrophil count &lt; 750 cells/microliter&#xD;
&#xD;
               5. Hemoglobin &lt; 9 mg/dL&#xD;
&#xD;
               6. Platelet count &lt; 100,000&#xD;
&#xD;
         12. Refusal or inability to comply with study procedures to the extent that it is&#xD;
             potentially harmful to the participant or to the integrity of the study data.&#xD;
&#xD;
         13. Has donated blood/plasma within four weeks before vaccination.&#xD;
&#xD;
         14. Is pregnant or breastfeeding, or intends to become pregnant over the course of the&#xD;
             study.&#xD;
&#xD;
         15. Is unable to commit to the follow-up visits and or has unreliable access to a&#xD;
             telephone for follow-up contacts, either by self-admission (self-reporting) or in the&#xD;
             opinion of the investigator.&#xD;
&#xD;
         16. Any other condition the investigator believes would interfere with the participant s&#xD;
             ability to provide informed consent, comply with study instructions, or that might&#xD;
             confound the interpretation of the study results or put the participant at undue risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Freeman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2017-I-0017.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Sowerwine KJ, Holland SM, Freeman AF. Hyper-IgE syndrome update. Ann N Y Acad Sci. 2012 Feb;1250:25-32. doi: 10.1111/j.1749-6632.2011.06387.x. Epub 2012 Jan 23. Review.</citation>
    <PMID>22268731</PMID>
  </reference>
  <reference>
    <citation>Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers C, Phan QT, Filler SG, Yeaman MR, Edwards JE Jr. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis. 2006 Jul 15;194(2):256-60. Epub 2006 Jun 6.</citation>
    <PMID>16779733</PMID>
  </reference>
  <reference>
    <citation>Liu Y, Filler SG. Candida albicans Als3, a multifunctional adhesin and invasin. Eukaryot Cell. 2011 Feb;10(2):168-73. doi: 10.1128/EC.00279-10. Epub 2010 Nov 29. Review.</citation>
    <PMID>21115738</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2016</study_first_posted>
  <results_first_submitted>June 22, 2020</results_first_submitted>
  <results_first_submitted_qc>June 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2020</results_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AD-HIES</keyword>
  <keyword>Anti-rAls3 Antibody</keyword>
  <keyword>Staphylococcus Aureus</keyword>
  <keyword>Candida Albicans</keyword>
  <keyword>RNA Transcriptome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Job Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02996448/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Healthy volunteers were not enrolled to the study due to the early termination. The three subjects enrolled were those with AD-HIES.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vaccination Group, Single Arm Study</title>
          <description>Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.&#xD;
NDV-3A: A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated due to adverse effects</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vaccination Group- Single Arm Study</title>
          <description>Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.&#xD;
NDV-3A: A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="19" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Each Group With at Least a Four-fold Increase in Anti rAls3 Antibody Titer.</title>
        <description>Antibody titer</description>
        <time_frame>2 weeks after vaccination</time_frame>
        <population>As study was stopped prematurely due to safety concerns, the data was not obtained.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Recipients</title>
            <description>Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.&#xD;
NDV-3A: A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Each Group With at Least a Four-fold Increase in Anti rAls3 Antibody Titer.</title>
          <description>Antibody titer</description>
          <population>As study was stopped prematurely due to safety concerns, the data was not obtained.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events That Led to Study Termination.</title>
        <time_frame>Up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vaccination Group- Single Arm Study</title>
            <description>Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.&#xD;
NDV-3A: A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events That Led to Study Termination.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-Als3 Antibody Titers at 6 Months After Vaccination in Patients With AD HIES and Healthy Volunteers.</title>
        <time_frame>6 months</time_frame>
        <population>Data were not collected due to premature termination of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccination Group- Single Arm Study</title>
            <description>Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.&#xD;
NDV-3A: A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Als3 Antibody Titers at 6 Months After Vaccination in Patients With AD HIES and Healthy Volunteers.</title>
          <population>Data were not collected due to premature termination of study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vaccination Group- Single Arm Study</title>
          <description>Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.&#xD;
NDV-3A: A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema exacerbation</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alexandra Freeman</name_or_title>
      <organization>NIAID, NIH</organization>
      <phone>301-594-9045</phone>
      <email>freemaal@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

